Navigation Links
FDA Approves 1st Skin Patch to Combat Migraines

By Amanda Gardner
HealthDay Reporter

MONDAY, Jan. 21 (HealthDay News) -- A skin patch for the treatment of migraines, and the intense waves of nausea that often accompany these debilitating headaches, has been approved by the U.S. Food and Drug Administration.

Called Zecuity, the patch contains sumatriptan, one of the most widely prescribed medications for migraines.

According to Dr. Fawad Khan, a neurologist with Ochsner Neuroscience Institute in New Orleans, few drugs are approved for the treatment of acute, symptomatic migraine. To complicate matters, many migraine sufferers can also experience severe bouts of nausea and vomiting.

Another expert described the problem this way.

"I've had some patients where the nausea and vomiting was so bad they couldn't even swallow a pill," said Nancy Waltman, a nurse practitioner with the University of Nebraska Medical Center College of Nursing, Lincoln Division.

A nasal spray is available, as is an injection, but many patients aren't comfortable with these options, Khan and Waltman noted.

Khan said the Zecuity patch is "simple, efficient and can deliver the exact amount of dosage with minimal variability."

The patch is attached to the upper arm or thigh, and when the patient pushes a button the drug is delivered through the skin. Zecuity, which is battery-operated, delivers 6.5 milligrams of sumatriptan over the course of about five hours and can relieve nausea, as well as reduce sensitivity to light and sound.

NuPathe Inc., which makes Zecuity, hopes to have the patch on the market later this year.

Research involving 800 patients ultimately led to the approval of Zecuity. One study found that 18 percent of patients using the patch were headache-free after two hours, compared with 9 percent of those using an inactive placebo. About half achieved a reduction in their headache after two hours, compared with 29 percent of those using the placebo.

And 84 percent of patients using the patch were relieved of their nausea, compared with 63 percent of those in the placebo group, according to a company news release.

The most frequent side effects were pain at the site of application along with tingling, itching, warmth and discomfort.

Patients with heart disease or who are using antidepressants known as selective serotonin reuptake inhibitors should also be careful when taking sumatriptans, said Waltman, who added that she thought the patches "are wonderful."

One concern, though, is cost, Waltman cautioned.

It's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.

In general, though, "the more options that are available to migraine headache patients, the better," Waltman said. "Migraine patients tend to be underdiagnosed and undertreated and inappropriately treated."

NuPathe CEO Armando Anido told Bloomberg News, "We anticipate the product will be available for sale in the fourth quarter of this year."

More information

The U.S. National Library of Medicine has more about migraines.

SOURCES: Fawad Khan, M.D., neurologist, Ochsner Neuroscience Institute, New Orleans; Nancy Waltman, Ph.D., nurse practitioner, University of Nebraska Medical Center College of Nursing, Lincoln Division; NuPathe Inc., news release, Jan. 17, 2013; Bloomberg News

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
2. FDA Approves New Type of Flu Vaccine
3. FDA Approves New Once-a-Day HIV Pill
4. FDA Approves Flu Vaccine for Coming Season
5. FDA Approves 2nd New Weight-Loss Drug
6. FDA Approves 1st Pill to Help Prevent HIV Infection
7. FDA Approves First New Weight-Loss Drug in More Than a Decade
8. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
9. FDA Approves Combo Shot for Meningitis, Hib in Kids
10. FDA Approves Generic Versions of Plavix
11. Measles vaccine given with a microneedle patch could boost immunization programs
Post Your Comments:
Related Image:
FDA Approves 1st Skin Patch to Combat Migraines
(Date:11/27/2015)... ... 28, 2015 , ... There is only one major question facing all law ... , This question has not been an easy question to answer. Especially when the ... the younger workforce don’t share the same discipline around working long hours. , ...
(Date:11/27/2015)... ... 27, 2015 , ... A team of Swiss doctors has released a report ... has just posted the findings on the website. Click here to read the ... 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... use in Final Cut Pro X. With ProSidebar: Fasion, video editors can easily ... use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop zones, ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Consultants has prided itself for not only fulfilling the needs of advisers and ... at an affordable price and providing top-tier customer service. However, there's always room ...
(Date:11/27/2015)... Francisco, California (PRWEB) , ... November 27, 2015 , ... ... Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's ... at the Canterbury House at the University of Michigan in Ann Arbor. The According ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... and NUREMBERG, Germany , Nov. 29, ... leader Ziehm Imaging invites attendees to experience the most ... market. The highlight on display is Ziehm Vision RFD ... that provides a 16 cm edge length per scan ... Hybrid Edition, the first fully motorized mobile C-arm in ...
(Date:11/27/2015)... --> --> ... The potential to save costs, improve treatment quality and ... fully exploited as yet. Here, particular emphasis is placed ... mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/26/2015)... India , November 27, ... --> --> ... personal emergency response system (PERS) ... steadily for 5 years with ... region expected to see a ...
Breaking Medicine Technology: